CN103126974B - 一种凝胶剂 - Google Patents
一种凝胶剂 Download PDFInfo
- Publication number
- CN103126974B CN103126974B CN201110390623.0A CN201110390623A CN103126974B CN 103126974 B CN103126974 B CN 103126974B CN 201110390623 A CN201110390623 A CN 201110390623A CN 103126974 B CN103126974 B CN 103126974B
- Authority
- CN
- China
- Prior art keywords
- gel
- buffer
- buffer solution
- sodium
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 238000007865 diluting Methods 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 239000007924 injection Substances 0.000 claims description 39
- 238000002347 injection Methods 0.000 claims description 39
- 229940090044 injection Drugs 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 32
- 239000007853 buffer solution Substances 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 19
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 13
- 229920002125 Sokalan® Polymers 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 229960001631 carbomer Drugs 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 10
- 239000008363 phosphate buffer Substances 0.000 claims description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000007981 phosphate-citrate buffer Substances 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 8
- -1 polyoxyethylene Polymers 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000007979 citrate buffer Substances 0.000 claims description 6
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical class COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 claims description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
- 229940072056 alginate Drugs 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 5
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 5
- 239000003961 penetration enhancing agent Substances 0.000 claims description 5
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 4
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 4
- 229940093181 glucose injection Drugs 0.000 claims description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 4
- 235000019477 peppermint oil Nutrition 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 3
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims description 2
- 229960000583 acetic acid Drugs 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 239000000648 calcium alginate Substances 0.000 claims description 2
- 229960002681 calcium alginate Drugs 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 235000010408 potassium alginate Nutrition 0.000 claims description 2
- 239000000737 potassium alginate Substances 0.000 claims description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940080818 propionamide Drugs 0.000 claims description 2
- 150000003239 pyrrolones Chemical class 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 238000005260 corrosion Methods 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000004821 distillation Methods 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 55
- 239000012153 distilled water Substances 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229930003268 Vitamin C Natural products 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 235000019154 vitamin C Nutrition 0.000 description 8
- 239000011718 vitamin C Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- 239000003182 parenteral nutrition solution Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 235000011083 sodium citrates Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 4
- 229960003866 cefaloridine Drugs 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 239000007836 KH2PO4 Substances 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 229960001790 sodium citrate Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000008923 Qingkailing Substances 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229940082484 carbomer-934 Drugs 0.000 description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical compound OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- OLUNPKFOFGZHRT-YGCVIUNWSA-N Naftifine hydrochloride Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OLUNPKFOFGZHRT-YGCVIUNWSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229950005040 cefathiamidine Drugs 0.000 description 1
- JYXACOFERDBGGQ-RHSMWYFYSA-N cefathiamidine Chemical compound S1CC(COC(C)=O)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CSC(NC(C)C)=NC(C)C)[C@H]21 JYXACOFERDBGGQ-RHSMWYFYSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002417 cefoperazone sodium Drugs 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- LKAPTZKZHMOIRE-UHFFFAOYSA-N chitose Natural products OCC1OC(C=O)C(O)C1O LKAPTZKZHMOIRE-UHFFFAOYSA-N 0.000 description 1
- 229940020010 ciprofloxacin injection Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940073541 econopred Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960003979 naftifine hydrochloride Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000002951 street drug Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004996 sulbactam pivoxyl Drugs 0.000 description 1
- OHPVYKXTRACOSQ-ZJUUUORDSA-N sulbactam pivoxyl Chemical compound O=S1(=O)C(C)(C)[C@H](C(=O)OCOC(=O)C(C)(C)C)N2C(=O)C[C@H]21 OHPVYKXTRACOSQ-ZJUUUORDSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明属于制剂领域，更具体地，本发明公开了一种凝胶剂、其制备方法和用途。本发明公开的凝胶剂动力粘度为10pa·s～1×105pa·s，其突破力和粘滞力分别在5g～500g范围；其制备方法包括将凝胶基质溶解得到凝胶基质液，调节pH值，后将含有其它组分的溶液加入凝胶基质液中，混匀即得。本发明公开的凝胶剂具有可稀释后进行涂抹应用且具有适用于不同药物的优点。
Description
技术领域
本发明属于制剂领域，更具体地，本发明公开了一种凝胶剂、其制备方法和用途。
背景技术
凝胶剂系指药物与能形成凝胶的辅料制成溶液、混悬或乳状液型的稠厚液体或半固体制剂。除另有规定外，凝胶剂限局部用于皮肤及体腔如鼻腔、阴道和直肠。乳状液型凝胶剂又称为乳胶剂。由高分子基质如西黄蓍胶制成的凝胶剂也可称为胶浆剂。小分子无机药物(如氢氧化铝)凝胶剂是由分散的药物小粒子以网状结构存在于液体中，属两相分散系统，也称混悬型凝胶剂。混悬型凝胶剂可有变性，静止时形成半固体而搅拌或振摇时成为液体。
凝胶剂基质属单相分散系统，有水性与油性之分。水性凝胶基质一般由水、甘油或丙二醇与纤维素衍生物、卡波姆和海藻酸盐、西黄蓍胶、明胶、淀粉等构成；油性凝胶基质由液状石蜡与聚乙烯或脂肪油与胶体硅或铝皂、锌皂构成。
在医药领域，对于不同的药物，一般都选用不同的辅料进行一系列的试验来制备得到不同的凝胶剂。由于药物的性质不同，迄今为止，还没有一种通用的，可广泛适用于不同药物可稀释后进行涂抹应用的凝胶剂。
发明内容
本发明公开了一种可以广泛适用于不同药物的可稀释后进行涂抹应用的凝胶剂，其特征在于此凝胶剂的动力粘度为10pa·s～1×105pa·s，其突破力(压力)和粘滞力(拉力)(触发点负载：0.2g；目标：20mm；测试速度：5mm/s；探头：TA3//100)分别在5g～500g范围。
更具体地，本发明公开的可稀释后进行涂抹应用的凝胶剂，含有凝胶基质、溶剂、保湿剂、防腐剂、渗透促进剂、缓冲剂和pH调节剂，其中凝胶基质∶溶剂∶保湿剂∶防腐剂∶渗透促进剂∶缓冲剂∶pH调节剂按重量比为0.1～20∶10～90∶1～30∶0.001～5∶0.1～5∶0.01～30∶0.1～15。
其中所述的凝胶基质可选择纤维素衍生物、卡波姆、海藻酸盐、生物胶(西黄蓍胶、明胶等)、淀粉、聚乙烯醇、聚丙烯酸钠、聚丙酰胺、透明质酸钠、医用几丁糖、聚氧乙烯醇之一或其组合，其中纤维素衍生物可以为羟丙基甲基纤维素K4M、羟丙基甲基纤维素K15M、甲基纤维素、乙基纤维素、羧甲基纤维素钠；卡波姆可以为910、934、940、941、971、974、980、1342、Ultrez 10；海藻酸盐可以为海藻酸钠、海藻酸钙、海藻酸钾；
所述的溶剂可选择蒸馏水、乙醇、乙二醇、丙二醇之一或其组合；
所述的保湿剂可选择甘油、聚乙二醇、硅乳、尿素、神经酰胺、胶原蛋白之一或其组合，其中聚乙二醇可以为PEG200、PEG300、PEG400、PEG600；
所述的防腐剂可选择尼泊金酯、羟苯乙酯、苯甲酸、三氯叔丁醇、聚六亚甲基双胍盐酸盐、硫柳汞、洗必泰、苯扎溴铵之一或其组合，其中尼泊金酯可为尼泊金甲酯、尼泊金乙酯、尼泊金丙酯、尼泊金丁酯；
所述的渗透促进剂可选择油酸、氮酮、薄荷油、吐温、吡咯酮、二甲基亚砜及其类似物、月桂醇硫酸钠之一或其组合；
所述的缓冲剂可选择磷酸盐缓冲液、柠檬酸盐缓冲液、磷酸盐-柠檬酸缓冲液、硼酸盐缓冲液之一或其组合，其中磷酸缓冲液为磷酸氢二钠缓冲液或pH＝6.86的磷酸盐缓冲液，柠檬酸盐缓冲液为柠檬酸-柠檬酸钠缓冲液、磷酸盐-柠檬酸缓冲液为磷酸氢二钠-柠檬酸缓冲液、硼酸盐缓冲液为硼砂-氯化钙缓冲液、
所述的pH值调节剂可选择氢氧化钠、氢氧化钾、氢氧化铝、三乙醇胺、硼酸、冰醋酸之一或其组合；
上述可稀释后进行涂抹应用的凝胶剂的制备过程如下：先将凝胶基质放入溶剂中自然溶胀，用pH调节剂调节pH值与所用缓冲液pH值相同或相近，再将保湿剂、防腐剂、渗透促进剂、缓冲剂配成溶液；将溶液加入凝胶基质液中，混匀，即得。
本发明公开的可稀释后进行涂抹应用的凝胶剂为水溶性凝胶基质载体，呈透明至半透明状的半固体状态，有一定粘度缓冲能力，应用时的稀释液为注射用药物制剂溶解液或药物注射剂，其中注射用药物制剂溶解液或药物注射剂∶凝胶剂按重量比为0.05∶1～10∶1。
具体地，上述药物注射剂可以为地塞米松磷酸钠注射液、盐酸利多卡因注射液、维生素C注射液、利巴韦林注射液、清开灵注射液、葡萄糖注射液、吡罗昔康注射液、复方倍他米松注射液、醋酸泼尼松龙注射液、氢化可的松注射液、醋酸曲安奈德注射液、氟尿嘧啶注射液、克霉唑溶液、哈西奈德溶液、甲胂酸钠注射液、诺氟沙星注射液、维生素B12注射液、盐酸环丙沙星注射液、盐酸洛美沙星注射液、盐酸萘替芬溶液、氧氟沙星注射液、依诺沙星注射液等，直接和凝胶剂混合均匀后应用；如果为注射用药物制剂类的固体药物制剂，例如：注射用头孢拉定、注射用青霉素钠(钾)、注射用头孢他啶、注射用头孢硫脒、注射用蜂毒、注射用头孢哌酮钠舒巴坦匹酯、注射用头孢唑林钠、注射用头孢噻肟钠、注射用维生素C、注射用阿奇霉素等，可以先将注射用药物制剂用注射用水、生理盐水或葡萄糖注射液溶解后再和凝胶剂混合均匀后应用。
说明书附图
附图1：实施例7产品采用质构仪测定图谱结果；
附图2：实施例7产品稀释至4倍后采用质构仪测定图谱结果；
附图3：实施例7产品稀释至8倍后采用质构仪测定图谱结果。
具体实施方式：
以下实施例、试验例仅仅是对本发明的进一步说明，不应理解为对本发明的限制。
实施例1
配制方法：将羟丙基甲基纤维素K4M及透明质酸钠放置在蒸馏水及乙醇中自然溶胀，用氢氧化铝溶液调节pH值约7.0；将聚乙二醇400、三氯叔丁醇、月桂醇硫酸钠、磷酸氢二钠-柠檬酸缓冲液(pH＝7.0)搅拌溶解，混匀，加入到羟丙基甲基纤维素K4M及透明质酸钠溶液中，不断搅拌，得半透明状凝胶，即得。
实施例2
配制方法：将羟丙基甲基纤维素K15M及透明质酸钠放置在部分蒸馏水中自然溶胀，用氢氧化钠溶液调节pH值约9；将胶原蛋白、尼泊金乙酯、氮酮、磷酸盐缓冲液(pH＝9.18)及剩余蒸馏水搅拌溶解，混匀，加入到羟丙基甲基纤维素K15M及透明质酸钠溶液中，不断搅拌，得半透明状凝胶，即得。
实施例3
配制方法：将卡波姆934放置在蒸馏水中自然溶胀，用三乙醇胺pH值约6.8；将甘油、羟苯乙酯、二甲基亚砜及磷酸盐缓冲液(pH＝6.86)搅拌混匀，加入到卡波姆934溶液中，不断搅拌，得半透明状凝胶即得。
实施例4
配制方法：将聚乙烯醇及透明质酸钠放置在部分蒸馏水及丙二醇中自然溶胀，用硼酸调节pH值约6.4；将聚乙二醇400、苯甲酸、吐温80及柠檬酸-柠檬酸钠缓冲液(pH＝6.4)搅拌混匀，加入到聚乙烯醇及透明质酸钠溶液中，不断搅拌，得半透明状凝胶，pH值约6.4，即得。
实施例5
配制方法：将卡波姆940放置在蒸馏水中自然溶胀，用三乙醇胺调节pH值约7.0；将甘油、尼泊金丙酯、苯扎溴铵、月桂醇硫酸钠及磷酸氢二钠-柠檬酸缓冲液(pH＝7.0)搅拌混匀，加入到卡波姆940溶液中，不断搅拌，得半透明状凝胶，即得。
实施例6
配制方法：将海藻酸钠放置在蒸馏水及丙二醇中自然溶胀，用氢氧化钾溶液调节pH值为8.0；将甘油、尼泊金甲酯、薄荷油、硼砂-氯化钙缓冲液(pH＝8.0)及剩余的蒸馏水搅拌混匀，加入到海藻酸钠溶液中，不断搅拌，得半透明状凝胶，即得。
实施例7
配制方法：将卡波姆及透明质酸钠放置在蒸馏水中自然溶胀，用三乙醇胺调节pH值为7.0；将甘油、聚六亚甲基双胍盐酸盐、氮酮及磷酸氢二钠-柠檬酸缓冲液(pH＝7.0)搅拌混匀，加入到卡波姆及透明质酸钠溶液中，不断搅拌，得半透明状凝胶，即得。
实施例8
配制方法：将海藻酸钠放置在蒸馏水中自然溶胀，用氢氧化钾调节pH值约8.0；将甘油、尼泊金乙酯、聚六亚甲基双胍盐酸盐、薄荷油及磷酸盐缓冲液(pH＝9.18)搅拌混匀，加入到海藻酸钠溶液中，不断搅拌，得半透明状凝胶，即得。
试验例1一般常用凝胶剂稀释后粘度变化试验
将卡波姆15g放置在900ml蒸馏水中自然溶胀，取甘油50g、聚六亚甲基双胍盐酸盐2g、氮酮20g加入到上述卡波姆溶胀液中，不断搅拌，用三乙醇胺约13ml调节pH值为7.0，搅拌混匀；得半透明状凝胶。取该凝胶剂50g八份，分成两组，分别加5ml、10ml、25ml、50ml的蒸馏水或维生素C注射液，测定粘度，结果如表1所示：
表1
表1表明：一般常用凝胶剂采用蒸馏水稀释后粘度变化缓慢，但采用维生素C注射液稀释后粘度巨变，已不具备适用凝胶剂的性质。
试验例2：加入不同缓冲液的凝胶剂稀释后粘度变化试验
参照袁道强、黄建华主编的《生物化学实验和技术》中“附录19-常用缓冲液的配制”及《中华人民共和国药典》2010年版二部附录XVD“缓冲液”；以卡波姆为凝胶基质，选择pH为5.0～10.0七种缓冲液，即pH值接近于7。如下：
(1)乙酸-乙酸钠缓冲液(pH＝5.8)；
(2)柠檬酸-柠檬酸钠缓冲液(0.1mol/L，pH＝6.4)；
(3)磷酸盐缓冲液(pH＝6.86)
(4)磷酸氢二钠-柠檬酸缓冲液(pH＝7.0)；
(5)硼砂-氯化钙缓冲液(pH＝8.0)；
(6)三羟甲基氨基甲烷缓冲液(pH＝8.0)；
(7)磷酸氢二钠缓冲液(pH＝9.18)。
将卡波姆150g放置在8000ml蒸馏水中自然溶胀；取上述溶胀物815g七份。用三乙醇胺调节pH值与所用缓冲剂pH值相同(或相近)，各取甘油50g、聚六亚甲基双胍盐酸盐2g、氮酮20g及缓冲液100ml分别加入到上述卡波姆溶胀液中，搅拌混匀；得半透明状凝胶。取各自凝胶剂50g四份，分别加5ml、10ml、25ml、50ml的维生素C注射液，测定粘度，结果如表2所示：
表2
表2表明：缓冲液的加入对凝胶剂稀释后粘度变化有一定影响。但乙酸-乙酸钠缓冲液及三羟甲基氨基甲烷缓冲液影响不明显(加入10％维生素C注射液后基本不具备凝胶剂性质)，故此两种缓冲液没有必要应用；而另五种缓冲液均能延缓粘度变化(加入1倍量维生素C注射液后仍具备较适宜的粘度)；因此，可选择柠檬酸-柠檬酸钠缓冲液、磷酸盐缓冲液、磷酸氢二钠-柠檬酸缓冲液、硼砂-氯化钙缓冲液、磷酸氢二钠缓冲液五种缓冲液的加入来减缓粘度的变化。
试验例3：压力、拉力测定试验
质构仪(物性测试仪)可对样品的物性概念做出准确表述，它使用统一的测试方法，是量化和精确的测量仪器。
质构仪的实验方法已经通过了许多国际和国家标准，并且标准数量还在逐渐增加，如AACC(美国谷物化学家协会)，AOAC(国际凝胶测试协会)，ISO，BS(英国国家标准)等。物性测试仪可广泛应用于食品、化工、医药、化妆品等相关行业，提供最精确的感官数据。
其中，利用平板探头下压一定厚度的相同体积的凝胶，从而得出不同凝胶软硬程度如何，所测正向力值(即突破力)越大，硬度越大；上提时，得出不同凝胶粘性的大小，该反向力值(即粘滞力)越大，粘性也就越大。
质构仪：
生产厂家：美国博勒飞
型号：CT3-1500
测定参数：触发点负载：0.2g
目标：20mm
测试速度：5mm/s
探头：TA3//100
温度：25℃
实施例7产品采用质构仪测定数据结果如表3所示：
表3
| 计数 | 时间 | 距离 | 负荷 |
| (s) | (mm) | (g) | |
| 1 | 0.1 | 0.48 | 28 |
| 2 | 0.2 | 0.98 | 10.6 |
| 3 | 0.3 | 1.48 | 23.4 |
| 4 | 0.4 | 1.98 | 17.6 |
| 5 | 0.5 | 2.49 | 22.6 |
| 6 | 0.6 | 2.99 | 30.4 |
| 7 | 0.7 | 3.52 | 26.4 |
| 8 | 0.8 | 4.02 | 32.6 |
| 9 | 0.9 | 4.52 | 35.2 |
| 10 | 1 | 5.02 | 32.4 |
| 11 | 1.1 | 5.52 | 45.2 |
| 12 | 1.2 | 6.02 | 42.4 |
| 13 | 1.3 | 6.52 | 44.6 |
| 14 | 1.4 | 7.02 | 47.4 |
| 15 | 1.5 | 7.52 | 49.8 |
| 16 | 1.6 | 8.02 | 47.6 |
| 17 | 1.7 | 8.54 | 53.6 |
| 18 | 1.8 | 9.04 | 52.8 |
| 19 | 1.9 | 9.54 | 55.4 |
| 20 | 2 | 10.04 | 56.4 |
| 21 | 2.1 | 10.55 | 56 |
| 22 | 2.2 | 11.05 | 55.4 |
| 23 | 2.3 | 11.55 | 63.4 |
| 24 | 2.4 | 12.05 | 58.6 |
| 25 | 2.5 | 12.55 | 59.4 |
| 26 | 2.6 | 13.1 | 65.8 |
| 27 | 2.7 | 13.63 | 61 |
| 28 | 2.8 | 14.13 | 64.4 |
| 29 | 2.9 | 14.63 | 63.4 |
| 30 | 3 | 15.12 | 63.8 |
| 31 | 3.1 | 15.63 | 66.2 |
| 32 | 3.2 | 16.13 | 66.8 |
| 33 | 3.3 | 16.63 | 64.2 |
| 34 | 3.4 | 17.13 | 67.4 |
| 35 | 3.5 | 17.63 | 67.8 |
| 36 | 3.6 | 18.13 | 68.6 |
| 37 | 3.7 | 18.66 | 76.6 |
| 38 | 3.8 | 19.16 | 78.8 |
| 39 | 3.9 | 19.66 | 80 |
| 40 | 4 | 19.85 | 36.6 |
| 41 | 4.1 | 19.35 | 23.4 |
| 42 | 4.2 | 18.85 | -7.6 |
| 43 | 4.3 | 18.35 | -18.6 |
| 44 | 4.4 | 17.84 | -26 |
| 45 | 4.5 | 17.34 | -34.4 |
| 46 | 4.6 | 16.84 | -43.6 |
| 47 | 4.7 | 16.31 | -42.4 |
| 48 | 4.8 | 15.81 | -49.2 |
| 49 | 4.9 | 15.32 | -46.4 |
| 50 | 5 | 14.82 | -47.4 |
| 51 | 5.1 | 14.32 | -53.6 |
| 52 | 5.2 | 13.77 | -51.8 |
| 53 | 5.3 | 13.28 | -53 |
| 54 | 5.4 | 12.77 | -58.6 |
| 55 | 5.5 | 12.27 | -50.6 |
| 56 | 5.6 | 11.74 | -52.4 |
| 57 | 5.7 | 11.24 | -53.4 |
| 58 | 5.8 | 10.75 | -49 |
| 59 | 5.9 | 10.24 | -52 |
| 60 | 6 | 9.74 | -51.2 |
| 61 | 6.1 | 9.24 | -47.6 |
| 62 | 6.2 | 8.74 | -48.2 |
| 63 | 6.3 | 8.24 | -50.8 |
| 64 | 6.4 | 7.73 | -43 |
| 65 | 6.5 | 7.23 | -42.8 |
| 66 | 6.6 | 6.71 | -41.6 |
| 67 | 6.7 | 6.2 | -34.4 |
| 68 | 6.8 | 5.71 | -42.6 |
| 69 | 6.9 | 5.21 | -37.6 |
| 70 | 7 | 4.7 | -37.4 |
| 71 | 7.1 | 4.2 | -35 |
| 72 | 7.2 | 3.7 | -31.2 |
| 73 | 7.3 | 3.2 | -26 |
| 74 | 7.4 | 2.69 | -31 |
| 75 | 7.5 | 2.2 | -31 |
| 76 | 7.6 | 1.67 | -27 |
| 77 | 7.7 | 1.12 | -24 |
| 78 | 7.8 | 0.62 | -22 |
| 79 | 7.9 | 0.12 | -27.6 |
| 80 | 8 | -0.38 | -23.8 |
| 81 | 8.1 | -0.88 | -12.2 |
| 82 | 8.2 | -1.39 | -15.8 |
| 83 | 8.3 | -1.89 | -14.6 |
| 84 | 8.4 | -2.38 | -1.6 |
| 85 | 8.5 | -2.89 | -16.8 |
| 86 | 8.6 | -3.41 | -6.2 |
| 87 | 8.7 | -3.91 | -12 |
| 88 | 8.8 | -4.41 | -12 |
| 89 | 8.9 | -4.91 | 4.6 |
| 90 | 9 | -5.41 | -0.4 |
| 91 | 9.1 | -5.91 | -15.2 |
| 92 | 9.2 | -6.41 | 3.2 |
| 93 | 9.3 | -6.92 | 3 |
| 94 | 9.4 | -7.42 | -6 |
| 95 | 9.5 | -7.92 | 6.8 |
| 96 | 9.6 | -8.45 | 2 |
| 97 | 9.7 | -8.95 | -5 |
| 98 | 9.8 | -9.45 | 5.2 |
| 99 | 9.9 | -9.95 | 2 |
| 100 | 10 | -10.45 | 1.8 |
| 101 | 10.1 | -10.95 | -9.6 |
| 102 | 10.2 | -11.45 | 7 |
| 103 | 10.3 | -12.01 | -8 |
| 104 | 10.4 | -12.51 | 7.8 |
| 105 | 10.5 | -13.01 | -0.4 |
| 106 | 10.6 | -13.53 | 0.2 |
| 107 | 10.7 | -14.03 | -2.8 |
| 108 | 10.8 | -14.54 | -8 |
| 109 | 10.9 | -15.04 | -4 |
| 110 | 11 | -15.54 | 7 |
| 111 | 11.1 | -16.04 | -4.6 |
| 112 | 11.2 | -16.54 | -1.6 |
| 113 | 11.3 | -17.04 | 6.4 |
| 114 | 11.4 | -17.54 | -4.6 |
| 115 | 11.5 | -18.04 | 3.2 |
| 116 | 11.6 | -18.57 | 0 |
| 117 | 11.7 | -19.07 | -6.6 |
| 118 | 11.8 | -19.57 | 4.6 |
| 119 | 11.9 | -20.07 | 0.2 |
| 120 | 12 | -20.57 | -6 |
| 121 | 12.1 | -21.07 | 7 |
| 122 | 12.2 | -21.57 | -1.4 |
| 123 | 12.3 | -22.07 | -10.4 |
| 124 | 12.4 | -22.57 | 4.6 |
| 125 | 12.5 | -23.07 | 0.4 |
| 126 | 12.6 | -23.6 | -3.8 |
| 127 | 12.7 | -24.1 | -0.2 |
| 128 | 12.8 | -24.65 | -2.8 |
| 129 | 12.9 | -25.15 | 4.8 |
| 130 | 13 | -25.65 | -0.6 |
实施例7产品采用质构仪测定图谱结果如附图1所示
结果表明：该产品突破力(压力)和粘滞力(拉力)(触发点负载：0.2g；目标：20mm；测试速度：5mm/s；探头：TA3//100)分别为80g及58.6g。
将实施例7产品稀释至4倍(50ml空白凝胶加蒸馏水150ml)后采用质构仪测定数据结果见表4
表4：
| # | 时间 | 距离 | 负荷 |
| (s) | (mm) | (g) | |
| 1 | 0.1 | 0.5 | 16.2 |
| 2 | 0.2 | 0.99 | -9.2 |
| 3 | 0.3 | 1.49 | 9.6 |
| 4 | 0.4 | 2.02 | 8.6 |
| 5 | 0.5 | 2.52 | 1.2 |
| 6 | 0.6 | 3.02 | 9 |
| 7 | 0.7 | 3.52 | 8.8 |
| 8 | 0.8 | 4.02 | 6.2 |
| 9 | 0.9 | 4.52 | 11.4 |
| 10 | 1 | 5.02 | 3.2 |
| 11 | 1.1 | 5.53 | 6.2 |
| 12 | 1.2 | 6.03 | 8.8 |
| 13 | 1.3 | 6.53 | 8 |
| 14 | 1.4 | 7.06 | 8.6 |
| 15 | 1.5 | 7.56 | 14.6 |
| 16 | 1.6 | 8.06 | 11.2 |
| 17 | 1.7 | 8.56 | 8.4 |
| 18 | 1.8 | 9.06 | 11.6 |
| 19 | 1.9 | 9.56 | 13.4 |
| 20 | 2 | 10.06 | 11 |
| 21 | 2.1 | 10.56 | 14.6 |
| 22 | 2.2 | 11.06 | 9.4 |
| 23 | 2.3 | 11.56 | 12.4 |
| 24 | 2.4 | 12.09 | 17.4 |
| 25 | 2.5 | 12.59 | 11.2 |
| 26 | 2.6 | 13.14 | 16.8 |
| 27 | 2.7 | 13.64 | 13.6 |
| 28 | 2.8 | 14.13 | 12.6 |
| 29 | 2.9 | 14.63 | 15.8 |
| 30 | 3 | 15.13 | 12.8 |
| 31 | 3.1 | 15.64 | 12.2 |
| 32 | 3.2 | 16.13 | 16.2 |
| 33 | 3.3 | 16.64 | 17.8 |
| 34 | 3.4 | 17.16 | 15 |
| 35 | 3.5 | 17.66 | 20.4 |
| 36 | 3.6 | 18.16 | 14 |
| 37 | 3.7 | 18.66 | 17.6 |
| 38 | 3.8 | 19.16 | 19.4 |
| 39 | 3.9 | 19.66 | 15.8 |
| 40 | 4 | 19.85 | -4.6 |
| 41 | 4.1 | 19.34 | 3.4 |
| 42 | 4.2 | 18.84 | 7.2 |
| 43 | 4.3 | 18.34 | -6.2 |
| 44 | 4.4 | 17.81 | -3.8 |
| 45 | 4.5 | 17.31 | -4.4 |
| 46 | 4.6 | 16.81 | -7.6 |
| 47 | 4.7 | 16.31 | -7.4 |
| 48 | 4.8 | 15.81 | -11.8 |
| 49 | 4.9 | 15.31 | -11.8 |
| 50 | 5 | 14.81 | -2.8 |
| 51 | 5.1 | 14.31 | -8.8 |
| 52 | 5.2 | 13.76 | -10.4 |
| 53 | 5.3 | 13.27 | -9.6 |
| 54 | 5.4 | 12.74 | -14.4 |
| 55 | 5.5 | 12.23 | -11 |
| 56 | 5.6 | 11.74 | -9.6 |
| 57 | 5.7 | 11.24 | -12.6 |
| 58 | 5.8 | 10.74 | -4 |
| 59 | 5.9 | 10.23 | -8.6 |
| 60 | 6 | 9.73 | -14.6 |
| 61 | 6.1 | 9.24 | -4.8 |
| 62 | 6.2 | 8.73 | -8.6 |
| 63 | 6.3 | 8.23 | -12.2 |
| 64 | 6.4 | 7.71 | -0.6 |
| 65 | 6.5 | 7.2 | -11 |
| 66 | 6.6 | 6.7 | -11.4 |
| 67 | 6.7 | 6.2 | -4.6 |
| 68 | 6.8 | 5.7 | -6.8 |
| 69 | 6.9 | 5.2 | -9 |
| 70 | 7 | 4.7 | -1.6 |
| 71 | 7.1 | 4.2 | -7.4 |
| 72 | 7.2 | 3.69 | -9.4 |
| 73 | 7.3 | 3.19 | -2.2 |
| 74 | 7.4 | 2.67 | -11.2 |
| 75 | 7.5 | 2.17 | -9.8 |
| 76 | 7.6 | 1.66 | -1.2 |
| 77 | 7.7 | 1.12 | -7.6 |
| 78 | 7.8 | 0.61 | -1 |
| 79 | 7.9 | 0.11 | -8.2 |
| 80 | 8 | -0.39 | -8.6 |
| 81 | 8.1 | -0.89 | -2 |
| 82 | 8.2 | -1.39 | -2.8 |
| 83 | 8.3 | -1.89 | -6.2 |
| 84 | 8.4 | -2.42 | 4 |
| 85 | 8.5 | -2.92 | -9.4 |
| 86 | 8.6 | -3.42 | -6.8 |
| 87 | 8.7 | -3.92 | 4.4 |
| 88 | 8.8 | -4.42 | -3.4 |
| 89 | 8.9 | -4.92 | -4.4 |
| 90 | 9 | -5.42 | 5.6 |
| 91 | 9.1 | -5.92 | -3.8 |
| 92 | 9.2 | -6.42 | -0.4 |
| 93 | 9.3 | -6.92 | 1.4 |
| 94 | 9.4 | -7.45 | -5.2 |
| 95 | 9.5 | -7.95 | -1.6 |
| 96 | 9.6 | -8.45 | 2.6 |
| 97 | 9.7 | -8.95 | -5.2 |
| 98 | 9.8 | -9.45 | 0.6 |
| 99 | 9.9 | -9.95 | 6 |
| 100 | 10 | -10.45 | -4.4 |
| 101 | 10.1 | -10.95 | 2.2 |
| 102 | 10.2 | -11.45 | 3.6 |
| 103 | 10.3 | -12.01 | -5.4 |
| 104 | 10.4 | -12.53 | 1.8 |
| 105 | 10.5 | -13.03 | -5.4 |
| 106 | 10.6 | -13.53 | 2.6 |
| 107 | 10.7 | -14.03 | 3 |
| 108 | 10.8 | -14.53 | -5.2 |
| 109 | 10.9 | -15.03 | 6.6 |
| 110 | 11 | -15.54 | 8.8 |
| 111 | 11.1 | -16.04 | -0.8 |
| 112 | 11.2 | -16.55 | -3 |
| 113 | 11.3 | -17.05 | 6 |
| 114 | 11.4 | -17.57 | -8 |
| 115 | 11.5 | -18.07 | 3.2 |
| 116 | 11.6 | -18.57 | -0.4 |
| 117 | 11.7 | -19.07 | -1.6 |
| 118 | 11.8 | -19.57 | 6.6 |
| 119 | 11.9 | -20.07 | 6.4 |
| 120 | 12 | -20.58 | -4.6 |
| 121 | 12.1 | -21.08 | -2.6 |
| 122 | 12.2 | -21.58 | 4 |
| 123 | 12.3 | -22.08 | -3.4 |
| 124 | 12.4 | -22.6 | 3.8 |
| 125 | 12.5 | -23.1 | -4.8 |
| 126 | 12.6 | -23.6 | -4.2 |
| 127 | 12.7 | -24.1 | 4 |
| 128 | 12.8 | -24.65 | -3.8 |
| 129 | 12.9 | -25.15 | 3.6 |
| 130 | 13 | -25.66 | 6 |
| 131 | 13.1 | -26.16 | -3.6 |
| 132 | 13.2 | -26.66 | -1.8 |
实施例7产品产品稀释至4倍(50ml空白凝胶加蒸馏水150ml)后采用质构仪测定图谱结果见附图2：
结果表明：该产品突破力(压力)和粘滞力(拉力)(触发点负载：0.2g；目标：20mm；测试速度：5mm/s；探头：TA3//100)分别为20.4g及14.6g。
将实施例7产品稀释8倍(50ml空白凝胶加蒸馏水350ml)后采用质构仪测定数据结果见表5：
表5
| # | 时间 | 距离 | 负荷 |
| (s) | (mm) | (g) | |
| 1 | 0.1 | 0.49 | 21.4 |
| 2 | 0.2 | 1 | 4 |
| 3 | 0.3 | 1.5 | -1.8 |
| 4 | 0.4 | 2 | -0.2 |
| 5 | 0.5 | 2.5 | -0.8 |
| 6 | 0.6 | 3 | 0 |
| 7 | 0.7 | 3.51 | 0 |
| 8 | 0.8 | 4 | 2.2 |
| 9 | 0.9 | 4.5 | 0 |
| 10 | 1 | 5.03 | 3.4 |
| 11 | 1.1 | 5.53 | 5 |
| 12 | 1.2 | 6.03 | -0.4 |
| 13 | 1.3 | 6.54 | 4 |
| 14 | 1.4 | 7.04 | 4.4 |
| 15 | 1.5 | 7.54 | -0.6 |
| 16 | 1.6 | 8.04 | 3 |
| 17 | 1.7 | 8.54 | 4.6 |
| 18 | 1.8 | 9.04 | -4 |
| 19 | 1.9 | 9.54 | 2.4 |
| 20 | 2 | 10.07 | 6.6 |
| 21 | 2.1 | 10.57 | 3.8 |
| 22 | 2.2 | 11.07 | 4.6 |
| 23 | 2.3 | 11.56 | 6.4 |
| 24 | 2.4 | 12.06 | 1.2 |
| 25 | 2.5 | 12.56 | 7.2 |
| 26 | 2.6 | 13.11 | 0 |
| 27 | 2.7 | 13.61 | 5 |
| 28 | 2.8 | 14.11 | 4 |
| 29 | 2.9 | 14.61 | -1.2 |
| 30 | 3 | 15.14 | 5.6 |
| 31 | 3.1 | 15.64 | 2.2 |
| 32 | 3.2 | 16.14 | 2.8 |
| 33 | 3.3 | 16.65 | 4.4 |
| 34 | 3.4 | 17.15 | 3.6 |
| 35 | 3.5 | 17.65 | 3.4 |
| 36 | 3.6 | 18.15 | 6.4 |
| 37 | 3.7 | 18.65 | 4.2 |
| 38 | 3.8 | 19.15 | 3.8 |
| 39 | 3.9 | 19.65 | 6 |
| 40 | 4 | 19.85 | -46.2 |
| 41 | 4.1 | 19.34 | 1.4 |
| 42 | 4.2 | 18.84 | 9.4 |
| 43 | 4.3 | 18.34 | 6.8 |
| 44 | 4.4 | 17.84 | 1.2 |
| 45 | 4.5 | 17.34 | 0.6 |
| 46 | 4.6 | 16.83 | -3.4 |
| 47 | 4.7 | 16.33 | 5.2 |
| 48 | 4.8 | 15.83 | 0 |
| 49 | 4.9 | 15.31 | 1.4 |
| 50 | 5 | 14.81 | 2.2 |
| 51 | 5.1 | 14.3 | 0 |
| 52 | 5.2 | 13.76 | 1.6 |
| 53 | 5.3 | 13.26 | 1.4 |
| 54 | 5.4 | 12.76 | -1 |
| 55 | 5.5 | 12.26 | 2.8 |
| 56 | 5.6 | 11.76 | -0.4 |
| 57 | 5.7 | 11.26 | 0 |
| 58 | 5.8 | 10.76 | 0.8 |
| 59 | 5.9 | 10.23 | -3 |
| 60 | 6 | 9.73 | 2 |
| 61 | 6.1 | 9.23 | -3.4 |
| 62 | 6.2 | 8.73 | -2.8 |
| 63 | 6.3 | 8.23 | 0.4 |
| 64 | 6.4 | 7.73 | 6 |
| 65 | 6.5 | 7.23 | -3.4 |
| 66 | 6.6 | 6.73 | -0.4 |
| 67 | 6.7 | 6.23 | 4 |
| 68 | 6.8 | 5.73 | -2.8 |
| 69 | 6.9 | 5.2 | 2.8 |
| 70 | 7 | 4.7 | 0.4 |
| 71 | 7.1 | 4.19 | -0.2 |
| 72 | 7.2 | 3.69 | 3.8 |
| 73 | 7.3 | 3.19 | 1.6 |
| 74 | 7.4 | 2.69 | -6 |
| 75 | 7.5 | 2.19 | -2.2 |
| 76 | 7.6 | 1.69 | 4.6 |
| 77 | 7.7 | 1.14 | -4.6 |
| 78 | 7.8 | 0.64 | 6.2 |
| 79 | 7.9 | 0.12 | -9.2 |
| 80 | 8 | -0.38 | -1 |
| 81 | 8.1 | -0.88 | -1.6 |
| 82 | 8.2 | -1.39 | -2.4 |
| 83 | 8.3 | -1.89 | 1.8 |
| 84 | 8.4 | -2.39 | 1.4 |
| 85 | 8.5 | -2.89 | -4.8 |
| 86 | 8.6 | -3.39 | 1.4 |
| 87 | 8.7 | -3.89 | -0.6 |
| 88 | 8.8 | -4.39 | -4.2 |
| 89 | 8.9 | -4.92 | 2.2 |
| 90 | 9 | -5.42 | 0 |
| 91 | 9.1 | -5.92 | -3.4 |
| 92 | 9.2 | -6.42 | 3.4 |
| 93 | 9.3 | -6.92 | 1.4 |
| 94 | 9.4 | -7.42 | -3.6 |
| 95 | 9.5 | -7.92 | 1.6 |
| 96 | 9.6 | -8.42 | -5.8 |
| 97 | 9.7 | -8.92 | -2.2 |
| 98 | 9.8 | -9.43 | -5 |
| 99 | 9.9 | -9.95 | -3.4 |
| 100 | 10 | -10.45 | 1.4 |
| 101 | 10.1 | -10.95 | 8.4 |
| 102 | 10.2 | -11.45 | -6.4 |
| 103 | 10.3 | -12 | 3.8 |
| 104 | 10.4 | -12.51 | -0.4 |
| 105 | 10.5 | -13.01 | -6 |
| 106 | 10.6 | -13.51 | -2 |
| 107 | 10.7 | -14.01 | 0.2 |
| 108 | 10.8 | -14.51 | -1.4 |
| 109 | 10.9 | -15.03 | 0.8 |
| 110 | 11 | -15.53 | -1.2 |
| 111 | 11.1 | -16.04 | 0 |
| 112 | 11.2 | -16.54 | 1.6 |
| 113 | 11.3 | -17.04 | -1.8 |
| 114 | 11.4 | -17.54 | 0.4 |
| 115 | 11.5 | -18.04 | 4.2 |
| 116 | 11.6 | -18.54 | -2.6 |
| 117 | 11.7 | -19.04 | -1 |
| 118 | 11.8 | -19.55 | 3.4 |
| 119 | 11.9 | -20.07 | -2.4 |
| 120 | 12 | -20.57 | 1.6 |
| 121 | 12.1 | -21.07 | 7 |
| 122 | 12.2 | -21.57 | -2 |
| 123 | 12.3 | -22.07 | -0.2 |
| 124 | 12.4 | -22.57 | 0.6 |
| 125 | 12.5 | -23.08 | -4.2 |
| 126 | 12.6 | -23.57 | 3.8 |
| 127 | 12.7 | -24.08 | 0.8 |
| 128 | 12.8 | -24.63 | -0.6 |
| 129 | 12.9 | -25.16 | 1 |
| 130 | 13 | -25.66 | -2 |
| 131 | 13.1 | -26.16 | 3.4 |
| 132 | 13.2 | -26.66 | 1.8 |
| 133 | 13.3 | -27.16 | -1 |
| 134 | 13.4 | -27.66 | -1.8 |
| 135 | 13.5 | -28.16 | 0.6 |
| 136 | 13.6 | -28.66 | 1.2 |
| 137 | 13.7 | -29.16 | 0.8 |
| 138 | 13.8 | -29.66 | -1.8 |
将实施例7产品稀释8倍(50ml空白凝胶加蒸馏水350ml)后采用质构仪测定图谱结果见附图3：
结果表明：该产品突破力(压力)和粘滞力(拉力)(触发点负载：0.2g；目标：20mm；测试速度：5mm/s；探头：TA3//100)分别为9.4g及9.2g。
从上述试验结果可以看出实施例7产品在稀释4、8倍后仍有很好的硬度和粘性。
本发明的申请人利用实施例1～6、实施例8的产品同实施例7的产品一样进行了上述试验，结果和上述试验结果一致，从而证明本发明的产品在稀释数倍后仍有很好的硬度和粘性。
试验例4：粘度测定试验
粘度计：
生产厂家：上海昌吉地质仪器有限公司
型号：NDJ-1B旋转粘度计
测定参数：转子(4号；注：稀释8倍后采用的转子为3号)
转速(3RPM)
温度(25℃)
实施例7产品采用粘度测定仪测定黏度结果8970PaS。
实施例7产品稀释至4倍(50ml空白凝胶加蒸馏水150ml)后采用粘度测定仪测定黏度结果：670PaS。
实施例7产品稀释至8倍(50ml空白凝胶加蒸馏水350ml)后采用粘度测定仪测定黏度结果：40PaS。
实施例1～6产品和实施例8产品也进行了和实施例7产品一样的上述试验，结果和实施例7产品进行的试验结果一致。
上述结果表明本品在稀释4、8倍后仍有很好的粘附性，较一般凝胶剂更好的稀释缓冲作用。
试验例：5：可稀释后进行涂抹应用的凝胶剂的使用
所用市售药品：
①注射用头孢拉定
规格：0.5g
批号：1104072
厂家：悦康药业集团有限公司
②地塞米松磷酸钠注射液
规格：2ml
批号：1032411
厂家：郑州卓峰药业有限公司
③盐酸利多卡因注射液
规格：5ml
批号：110402011
厂家：山西银湖制药有限责任公司
④维生素C注射液
规格：2ml
批号：1012412
厂家：郑州卓峰药业有限公司
⑤利巴韦林注射液
规格：1ml
批号：101125
厂家：山西太原药业有限公司
⑥清开灵注射液
规格：10ml
批号：11011562
厂家：河北神威药业有限公司
⑦生理盐水
规格：500ml
批号：A11011601
厂家：山东康宁药业有限公司
⑧葡萄糖注射液(5％)
规格：500ml
批号：A11051102
厂家：山东康宁药业有限公司
缓冲液的配制：
1、硼砂-氯化钙缓冲液(pH＝8.0)：
理论：取硼砂0.572g与氯化钙2.94g，加水约800ml溶解后，用1mol/L盐酸溶液约2.5ml调节pH值至8.0，加水稀释至1000ml，即得。
试验：称硼砂0.5722g与氯化钙2.9422g，加水800ml溶解后，用1mol/L盐酸溶液调节pH值至8.0，加水稀释至1000ml，摇匀，备用。(测pH7.99)
2、柠檬酸-柠檬酸钠缓冲液(0.1mol/L，pH＝6.4)：
(1)0.1mol/L柠檬酸的配制[柠檬酸(1水合物)分子量210.14]：
理论：称取柠檬酸21.01g加水1000ml溶解即得。
试验：称取柠檬酸10.5058g加水500ml溶解，备用。
(2)0.1mol/L柠檬酸钠的配制[柠檬酸钠(2水合物)分子量294.10]：
理论：称取柠檬酸钠29.41g加水1000ml溶解即得。
试验：称取柠檬酸钠5.8848g加水200ml溶解，备用。
最后量取上述配制好的0.1mol/L柠檬酸4.0ml和0.1mol/L柠檬酸钠36.0ml混匀，即得。(测试pH6.16)(后该缓冲液用0.1mol/L柠檬酸钠调节pH至6.37)
3、磷酸氢二钠-柠檬酸缓冲液(pH＝7.0)：
(1)0.1mol/L柠檬酸的配制[柠檬酸(1水合物)分子量210.14]：
同上；
(2)0.2mol/L磷酸氢二钠的配制[磷酸氢二钠(12水合物)分子量358.14]：
理论：称取磷酸氢二钠71.63g加水1000ml溶解即得。
试验：称取磷酸氢二钠14.3399g加水200ml溶解，备用。
最后量取上述配制好的0.1mol/L柠檬酸7.06ml和0.2mol/L磷酸氢二钠32.94ml混匀，即得。(测试pH7.00)
4、磷酸盐缓冲液(pH＝6.86)：
理论：1/15M的Na2HPO4溶液(11.876克纯的Na2HPO4·2H2O溶于1升蒸馏水中)及1/15M的KH2PO4溶液(9.078克纯的KH2PO4溶于1升蒸馏水中)将两种溶液等比例混匀即得。
试验：称取Na2HPO4·2H2O 5.9784g加水500ml溶解，备用。
试验：称取KH2PO4 4.5756g加水500ml溶解，备用。
两种溶液等比例混匀即得。(测试pH6.78)
按实例7产品进行配置{其中缓冲液【磷酸氢二钠-柠檬酸缓冲液(pH＝7.0)】用相同体积的的水替代}按1.5％卡波姆凝胶剂150g分别一次加入蒸馏水50ml或缓冲液(1、2、3、4)，再加入生理盐水注射液50ml及药品(①②③④⑤⑥)各50ml(注：药品为液体制剂的直接取50ml；药品为固体制剂的按说明书的适用方法中的稀释比例用生理盐水稀释制备50ml)。测粘度(用4号转子、3转/分钟)结果见表6：
表6的结果表明：加入药液后，使用缓冲剂较不用缓冲剂其粘度下降缓慢，其中以注射用头孢拉定、维生素C注射液变化最为明显，其中注射用头孢拉定变化比例将近10倍；维生素C注射液变化比例高于25倍。因此该凝胶剂可用，达到了本发明的目的。
Claims (7)
1.一种可稀释后进行涂抹应用的凝胶剂，其特征在于由凝胶基质、溶剂、保湿剂、防腐剂、渗透促进剂、pH调节剂和缓冲剂组成，不含有医药制剂；其中凝胶基质∶溶剂∶保湿剂∶防腐剂∶渗透促进剂∶缓冲剂∶pH调节剂按重量比为0.1～20∶10～90∶1～30∶0.001～5∶0.1～5∶0.01～30∶0.1～15；其中所述的渗透促进剂为油酸、氮酮、薄荷油、吐温、吡咯酮、二甲基亚砜、月桂醇硫酸钠之一或其组合；其中所述的缓冲剂为磷酸盐缓冲液、柠檬酸盐缓冲液、磷酸盐-柠檬酸缓冲液、硼酸盐缓冲液中一种或其组合，其中磷酸盐缓冲液为pH＝9的磷酸氢二钠缓冲液或pH＝6.86的磷酸盐缓冲液，柠檬酸盐缓冲液为柠檬酸-柠檬酸钠缓冲液、磷酸盐-柠檬酸缓冲液为磷酸氢二钠-柠檬酸缓冲液、硼酸盐缓冲液为硼砂-氯化钙缓冲液；
其中所述的可稀释后进行涂抹应用的凝胶剂的制备方法为先将凝胶基质放入溶剂中自然溶胀，用pH调节剂调节pH值与所用缓冲剂pH值相同或相近，再将保湿剂、防腐剂、渗透促进剂、缓冲剂配成溶液；将溶液加入凝胶基质液中，混匀，即得。
2.权利要求1所述的可稀释后进行涂抹应用的凝胶剂，其特征在于所述的凝胶基质为纤维素衍生物、卡波姆、海藻酸盐、淀粉、聚乙烯醇、聚丙烯酸钠、聚丙酰胺、透明质酸钠、医用几丁糖、聚氧乙烯醇中一种或其组合，其中纤维素衍生物为羟丙基甲基纤维素K4M、羟丙基甲基纤维素K15M、甲基纤维素、乙基纤维素、羧甲基纤维素钠；其中卡波姆为910、934、940、941、971、974、980、1342、Ultrez10；海藻酸盐为海藻酸钠、海藻酸钙、海藻酸钾。
3.权利要求1所述的可稀释后进行涂抹应用的凝胶剂，其特征在于所述的溶剂为蒸馏水、乙醇、乙二醇、丙二醇中一种或组合。
4.权利要求1所述的可稀释后进行涂抹应用的凝胶剂，其特征在于所述的保湿剂为甘油、聚乙二醇、硅乳、尿素、神经酰胺、胶原蛋白之一或其组合，其中聚乙二醇为PEG200、PEG300、PEG400、PEG600。
5.权利要求1所述的可稀释后进行涂抹应用的凝胶剂，其特征在于所述的防腐剂为尼泊金酯、苯甲酸、三氯叔丁醇、聚六亚甲基双胍盐酸盐、硫柳汞、洗必泰、苯扎溴铵之一或其组合，其中尼泊金酯为尼泊金甲酯、尼泊金乙酯、尼泊金丙酯、尼泊金丁酯。
6.权利要求1所述的可稀释后进行涂抹应用的凝胶剂，其特征在于所述的pH调节剂为氢氧化钠、氢氧化钾、氢氧化铝、三乙醇胺、硼酸、冰醋酸之一或其组合。
7.权利要求1所述的可稀释后进行涂抹应用的凝胶剂作为水溶性凝胶基质载体的应用，应用方法为将注射用药物制剂用注射用水、生理盐水或葡萄糖注射液溶解后再和凝胶剂混合均匀使用，或者将注射剂和凝胶剂混合均匀使用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110390623.0A CN103126974B (zh) | 2011-11-30 | 2011-11-30 | 一种凝胶剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110390623.0A CN103126974B (zh) | 2011-11-30 | 2011-11-30 | 一种凝胶剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103126974A CN103126974A (zh) | 2013-06-05 |
| CN103126974B true CN103126974B (zh) | 2018-04-10 |
Family
ID=48487856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110390623.0A Expired - Fee Related CN103126974B (zh) | 2011-11-30 | 2011-11-30 | 一种凝胶剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103126974B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105106459A (zh) * | 2015-09-19 | 2015-12-02 | 陈红 | 一种治疗浅度溃疡期压疮的中药凝胶剂及其制备方法 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103736138A (zh) * | 2013-12-22 | 2014-04-23 | 褚加冕 | 一种载银海藻酸钙医用敷料的制备方法 |
| CN107412885B (zh) * | 2014-01-13 | 2020-04-28 | 成都英诺新科技有限公司 | 一种助产用凝胶及其制备方法 |
| CN104673876B (zh) * | 2015-02-09 | 2017-08-15 | 广州绿洲生化科技股份有限公司 | 一种用于微生物检测的透明吸水凝胶及检测板 |
| CN107849100B (zh) * | 2015-04-09 | 2022-02-08 | 丝芭博株式会社 | 极性溶剂溶液及其制造方法 |
| JP6856828B2 (ja) | 2015-04-09 | 2021-04-14 | Ｓｐｉｂｅｒ株式会社 | 極性溶媒溶液及びその製造方法 |
| CN104971076A (zh) * | 2015-05-25 | 2015-10-14 | 北京中医药大学 | 一种稳定的蜂毒凝胶剂及其制备方法 |
| CA2896038C (en) | 2015-07-03 | 2022-08-09 | Glycobiosciences Inc. | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof |
| CN105031621B (zh) * | 2015-08-18 | 2018-07-03 | 安徽安科生物工程（集团）股份有限公司 | 重组人干扰素α2b凝胶及其制备方法 |
| CN105363060A (zh) * | 2015-11-13 | 2016-03-02 | 邢月军 | 具有止血镇痛功效的医用凝胶 |
| CN105920674A (zh) * | 2016-06-27 | 2016-09-07 | 林春梅 | 一种生物医用复合材料及其制备方法 |
| CN107184423A (zh) * | 2017-05-25 | 2017-09-22 | 广州市花安堂生物科技有限公司 | 一种高度透明涂抹即时化水的凝胶状化妆水及其制备方法 |
| CN110269958B (zh) * | 2018-03-17 | 2021-11-23 | 北京旭泽医药科技有限公司 | 一种含有卡波姆的助产凝胶组合物及其制备方法 |
| CN109289095B (zh) * | 2018-11-23 | 2021-03-26 | 淮海工学院 | 一种含盐酸利多卡因的肠镜凝胶剂及其制备方法 |
| CN109481435B (zh) * | 2018-12-29 | 2021-04-23 | 湖北绿无界生物科技有限公司 | 妇科用复方组合物 |
| CN109431968A (zh) * | 2018-12-29 | 2019-03-08 | 天津凯茵科技有限公司 | 基于克霉唑的妇科用复方组合物 |
| CN111393676B (zh) * | 2020-04-23 | 2022-09-13 | 华熙生物科技股份有限公司 | 一种阻止透明质酸或其盐凝胶灭菌粘度降低的方法 |
| CN112051190B (zh) * | 2020-09-02 | 2023-08-18 | 重庆科技学院 | 一种复合渗透酸渗透能力评价方法 |
| CN114259461B (zh) * | 2021-11-29 | 2023-09-12 | 海南全星制药有限公司 | 一种双氯芬酸钠凝胶及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1903174A (zh) * | 2006-08-16 | 2007-01-31 | 北京科信必成医药科技发展有限公司 | 克霉唑凝胶剂及其制备方法 |
| CN101288643A (zh) * | 2008-06-17 | 2008-10-22 | 杨喜鸿 | 含有他克莫司的凝胶剂组合物及其制备方法和药物应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100425237C (zh) * | 2005-09-28 | 2008-10-15 | 哈尔滨医科大学 | 复方盐酸西替利嗪凝胶剂 |
-
2011
- 2011-11-30 CN CN201110390623.0A patent/CN103126974B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1903174A (zh) * | 2006-08-16 | 2007-01-31 | 北京科信必成医药科技发展有限公司 | 克霉唑凝胶剂及其制备方法 |
| CN101288643A (zh) * | 2008-06-17 | 2008-10-22 | 杨喜鸿 | 含有他克莫司的凝胶剂组合物及其制备方法和药物应用 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105106459A (zh) * | 2015-09-19 | 2015-12-02 | 陈红 | 一种治疗浅度溃疡期压疮的中药凝胶剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103126974A (zh) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103126974B (zh) | 一种凝胶剂 | |
| Shchipunov et al. | A new precursor for the immobilization of enzymes inside sol–gel-derived hybrid silica nanocomposites containing polysaccharides | |
| Xie et al. | Interactions between tapioca starch and Mesona chinensis polysaccharide: Effects of urea and NaCl | |
| CN1112915C (zh) | 新的小核菌葡聚糖和包含新化合物的化妆品组合物 | |
| CN104470490B (zh) | 使用弹性混合物的化妆护理组合物及方法 | |
| Luo et al. | Preparation and properties of enzyme-modified cassava starch–zinc complexes | |
| Alves da Cunha et al. | Lasiodiplodan, an exocellular (1→ 6)-β-d-glucan from Lasiodiplodia theobromae MMPI: production on glucose, fermentation kinetics, rheology and anti-proliferative activity | |
| CN104086788B (zh) | 一种注射用修饰透明质酸钠凝胶 | |
| EP2922581B1 (en) | Mucoadhesive compositions comprising hyaluronic acid and chitosan for topical application | |
| Coviello et al. | Scleroglucan/borax: characterization of a novel hydrogel system suitable for drug delivery | |
| Yuan et al. | Influence of cyclodextrins on the gelation behavior of κ-carrageenan/konjac glucomannan composite gel | |
| CN104888224A (zh) | 一种两亲性多糖衍生物/泊洛沙姆温敏型原位水凝胶及其制备方法 | |
| CN102844367A (zh) | 水凝胶 | |
| CN114146020B (zh) | 一种注射美容产品及其制备方法和应用 | |
| CN105131348A (zh) | 一种无菌可注射材料 | |
| CN113429589B (zh) | 甘草酸基pH敏感型缓释水凝胶材料及其制备方法与应用 | |
| CN102755662B (zh) | 一种复合壳聚糖凝胶膜及其制备方法 | |
| Qiao et al. | Small and large oscillatory shear behaviors of gelatin/starch system regulated by amylose/amylopectin ratio | |
| Mohan et al. | Evaluation of gelling behavior of natural gums and their formulation prospects | |
| Wu et al. | The impact of different concentrations of hyaluronic acid on the pasting and microstructural properties of corn starch | |
| JPH03204804A (ja) | 皮膚化粧料 | |
| CN115671405B (zh) | 一种关节腔注射凝胶及其制备方法 | |
| CN117024615A (zh) | 一种海藻多糖衍生物的制备方法与应用 | |
| CN109381375A (zh) | 一种头皮护理用精油组合物及应用 | |
| Huang et al. | Enhancing frozen dough quality: Investigating the impact of soy Hull polysaccharide (SHP) on rheological properties and microstructure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Mian Document name: Notice of Termination of Patent Rights |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180410 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |